Related Experiment Video
Updated: Apr 16, 2026
05:23
Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
4.7K
CGRP mechanism antagonists and migraine management
Nazia Karsan1, Peter J Goadsby
1Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Current Neurology and Neuroscience Reports
|March 21, 2015
Summary
Calcitonin gene-related peptide (CGRP) is a key player in migraine pathophysiology. CGRP antagonists represent a promising new therapeutic strategy for managing debilitating migraine attacks.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Migraine is a complex neurological disorder characterized by severe disability.
- The vascular hypothesis of migraine is outdated; new research focuses on neural pathways.
- Calcitonin gene-related peptide (CGRP) is implicated in migraine mechanisms.
Purpose of the Study:
- To review the current status of calcitonin gene-related peptide (CGRP) antagonist therapies for migraine.
- To highlight recent clinical trials and the evidence supporting CGRP-based treatments.
- To discuss the future role of CGRP antagonists in migraine management.
Main Methods:
- Review of current literature on CGRP mechanisms in migraine.
- Analysis of recent clinical trial data for CGRP antagonist therapies.
- Discussion of the scientific evidence supporting novel migraine drugs.
Main Results:
- CGRP is released during migraine attacks and its administration can trigger migraines.
- CGRP receptor antagonists have demonstrated efficacy in aborting migraine attacks.
- Evidence from recent trials supports the therapeutic potential of CGRP antagonists.
Conclusions:
- CGRP-based mechanisms offer a novel target for migraine therapeutics.
- CGRP antagonist therapy is an emerging and promising approach to migraine management.
- Further research and development are expanding the role of these drugs in clinical practice.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
785
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
785
01:28Drugs Acting on Autonomic Ganglia: Blockers
1.9K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.9K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
3.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.7K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
910
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
910
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.6K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.6K
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
5.0K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
5.0K